Tirzepatide is a novel, investigational peptide belonging to the dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists class. Developed for the treatment of type 2 diabetes, tirzepatide combines the actions of both GIP and GLP-1 to enhance glycemic control. It stimulates insulin release and inhibits glucagon production in response to elevated blood sugar levels, contributing to improved blood glucose regulation. Additionally, tirzepatide is designed to address weight management, as it may induce weight loss. Clinical trials have shown promising results, demonstrating its potential as an effective and well-tolerated option for test subjects with type 2 diabetes.